Summary
55 / 100 · Bulios Score
What speaks for it
- Revenue grew by 30% a year over the last 3 years.
- It holds more cash than debt: $35.4M against $17.6M.
- Analysts expect revenue to grow by 14% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 85.0 AUD for 1 AUD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue grew by 38% a year over 5 years. Over the last 3 years it grew by 30% a year. For the next fiscal year analysts expect revenue to grow by 14%.
Growth in detailDoes it make money?
ReasonablyWhere 100 AUD of revenue goes
- Cost of sales 67 AUD
- Research and development 3.7 AUD
- Sales and administration 24 AUD
- Taxes and other -0.1 AUD
- Net profit 5.1 AUD
Net profit, industry median (Medical - Devices) 6.9 AUD
Out of every 100 AUD of revenue, 5.1 AUD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.9 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.